Literature DB >> 17453293

Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?

Guillaume Piessen1, Nicolas Briez, Jean-Pierre Triboulet, Christophe Mariette.   

Abstract

BACKGROUND: In patients who are nonresponders to primary radiochemotherapy (RCT), prognosis is poor, leading mostly to palliation. Salvage surgery may have a survival benefit otherwise complete. Our aim was to identify predictors of R0 resection in these patients.
METHODS: In 98 nonresponders with locally advanced infracarinal tumors, curative salvage surgery was attempted. Resection was R0 in 62.2% and incomplete in 37.8% of cases. Univariate and multivariate analyses included pre-RCT and post-RCT variables collected prospectively.
RESULTS: Overall survival was higher in the R0 resection group (18.4 vs 8.6 months, P < .001). Independent predictors of R0 resection were tumor height <or= 5 cm on barium swallow (P = .045) and aortic contact <or= 90 degrees on computed tomography (P = .039) evaluated after RCT. Three groups of patients were constructed: 1, tumor height <or= 5 cm with aortic contact <or= 90 degrees (n = 43); 2, tumor height between 6 and 10 cm with aortic contact <or= 90 degrees (n = 32); and 3, aortic contact > 90 degrees , irrespective of tumor height (n = 23). Rates of R0 resection were 81%, 53%, and 39%, respectively (P = .001).
CONCLUSION: Salvage esophagectomy should be systematically attempted in nonresponders with tumor height <or= 5 cm on barium swallow and aortic contact <or= 90 degrees on computed tomography and discussed case by case for other patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453293     DOI: 10.1245/s10434-007-9405-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  1 in total

1.  Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Xiaoli Zhang; Minghuan Li; Xue Meng; Li Kong; Yan Zhang; Guangsheng Wei; Xiqin Zhang; Fang Shi; Man Hu; Guoli Zhang; Jinming Yu
Journal:  Radiat Oncol       Date:  2014-02-26       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.